Marieke van Son

131 TOXICITY AFTER ULTRAFOCAL SALVAGE HDR-BRACHYTHERAPY Table 3 – Association of pre-treatment characteristics with grade ≥2 toxicity Domain 95% CI OR lower upper p-value GU Baseline toxicity Baseline IPSS Urethra D10% (Gy) Bladder D1cc (Gy) Prostate size (cc) Tumor stage >T2 Size of the CTV (cc) Primary LDR-BT (versus EBRT) Interval primary–salvage treatment (years) Previous salvage treatment History of TURP Number of brachytherapy catheters used 14.76 1.11 1.28 1.02 1.02 1.10 1.04 2.79 1.07 0.72 2.46 0.83 6.14 1.01 1.05 0.84 0.98 0.29 0.89 0.90 0.95 0.05 0.34 0.59 35.50 1.23 1.56 1.24 1.05 4.20 1.21 8.70 1.22 11.31 17.95 1.16 <0.01 0.03 0.01 0.85 0.36 0.89 0.61 0.08 0.26 0.81 0.37 0.28 ED Baseline toxicity Baseline IIEF Dorsolateral location of the tumor Prostate size (cc) Tumor stage >T2 Size of the CTV (cc) Primary LDR-BT (versus EBRT) Interval primary–salvage treatment (years) Previous salvage treatment Previous use of ADT* Number of brachytherapy catheters used 73.70 0.97 2.81 1.00 0.45 1.04 1.73 1.10 0.31 1.58 1.04 15.97 0.87 0.25 0.95 0.07 0.85 0.28 0.88 0.01 0.17 0.64 340.03 1.08 31.19 1.05 2.76 1.27 10.62 1.37 12.01 15.08 1.68 <0.01 0.56 0.40 0.96 0.39 0.70 0.55 0.40 0.53 0.69 0.88 Legend: GU: genitourinary, ED: erectile dysfunction, IPSS: international prostate symptoms score, CTV: clinical tumor volume, LDR-BT: low-dose-rate brachytherapy, EBRT: external beam radiotherapy, TURP: transurethral resection of the prostate, IIEF: international index of erectile function, ADT: androgen deprivation therapy, OR: odds ratio, 95% CI: 95% confidence interval. * As part of primary treatment (neo-adjuvant or adjuvant). 7